Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aminotransferases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Aminotransferases. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-001762-13 Sponsor Protocol Number: 747-401 Start Date*: 2018-08-01
    Sponsor Name:Intercept Pharmaceuticals, Inc.
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa...
    Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001449-13 Sponsor Protocol Number: XM02-04-INT Start Date*: 2004-08-03
    Sponsor Name:BioGeneriX AG
    Full Title: Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.
    Medical condition: Patients with Non-Hodgkin-Lymphoma receiving chemotherapy and developing Neutropenia due to chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001452-36 Sponsor Protocol Number: XM02-02-INT Start Date*: 2004-06-30
    Sponsor Name:BioGeneriX
    Full Title: Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study
    Medical condition: Patients with breast cancer high risk stage II or stage III/IV (classification according to American Joint Committee on Cancer [AJCC] receiving chemotherapy and developing Neutropenia due to chemot...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003108-10 Sponsor Protocol Number: GOING Start Date*: 2020-01-14
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: The GOING Study: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005660-86 Sponsor Protocol Number: 06_DOG03_107 Start Date*: 2006-07-19
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma
    Medical condition: Advanced Gastric/Oesophageal Adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003553-27 Sponsor Protocol Number: WF10-05-001 Start Date*: 2005-11-28
    Sponsor Name:DIMETHAID AG
    Full Title: A SINGLE CENTRE, OPEN LABEL, PHASE II CLINICAL STUDY OF THE ADJUNCTIVE BENEFIT OF WF10 TO STANDARD CAPECITABINE CHEMOTHERAPY IN SUBJECTS WITH UNRESECTABLE PANCREATIC CANCER
    Medical condition: UNRESECTABLE PANCREATIC CANCER
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001564-37 Sponsor Protocol Number: AGMT_HIV1 Start Date*: 2013-12-02
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ra...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001200-20 Sponsor Protocol Number: CSET 1287 Start Date*: 2007-06-01
    Sponsor Name:Institut Gustave Roussy
    Full Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer
    Medical condition: adenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017788-40 Sponsor Protocol Number: KEO09069EST Start Date*: 2010-10-20
    Sponsor Name:CRLCC Alexis Vautrin
    Full Title: Etude de phase II randomisée multicentrique évaluant l'efficacité d’estramustine phosphate (Estracyt ®) chez des patientes présentant un cancer du sein métastatique HER2- / RH+ ayant déjà reçu un t...
    Medical condition: Metastases breast cancer in women already treated with aromatase inhibitors.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001270-24 Sponsor Protocol Number: A3671014 Start Date*: 2007-02-13
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum
    Medical condition: Refractory meatstatic adenocarcinoma of the colon or rectum
    Disease: Version SOC Term Classification Code Term Level
    8,0 10061289 VTc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002826-70 Sponsor Protocol Number: A3671008 Start Date*: 2005-11-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, 10017, USA
    Full Title: A Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ticilimumab in patients with advanced refractory and/or relapsed melanoma
    Medical condition: Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004418-32 Sponsor Protocol Number: U31402-A-U202 Start Date*: 2020-10-30
    Sponsor Name:DAIICHI SANKYO, INC
    Full Title: A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)
    Medical condition: Advanced or metastatic colorectal cancer (CRC) which is resistant, refractory, or intolerant to at least 2 prior lines of therapy, that must include all of the following agents: fluoropyrimidine, i...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003692-35 Sponsor Protocol Number: ZKSJ0109 Start Date*: 2019-06-13
    Sponsor Name:Friedrich Schiller University Jena
    Full Title: Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure
    Medical condition: acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002344-23 Sponsor Protocol Number: 2020/490 Start Date*: 2020-08-19
    Sponsor Name:CHU de Besançon
    Full Title: Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinoma An open-label phase II
    Medical condition: Metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000741-46 Sponsor Protocol Number: 2017/2523 Start Date*: 2017-10-06
    Sponsor Name:Gustave Roussy
    Full Title: RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
    Medical condition: Pancreatic well differentiated neuroendocrine tumors (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004385-34 Sponsor Protocol Number: ICM_2013/09 Start Date*: 2014-05-27
    Sponsor Name:Institut régional du Cancer - Montpellier - Val d'Aurelle
    Full Title: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial
    Medical condition: advanced Biliary Tract Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001244-56 Sponsor Protocol Number: LiCTOP-C-001 Start Date*: 2013-07-23
    Sponsor Name:Department of Pharmacy, Uppsala University
    Full Title: An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipi...
    Medical condition: Intermediate hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002827-15 Sponsor Protocol Number: A3671009 Start Date*: 2006-01-19
    Sponsor Name:Pfizer Ltd. [...]
    1. Pfizer Ltd.
    2.
    Full Title: Phase 3, open label, randomized, comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025650 VTc
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Completed) BE (Completed) SE (Completed) GR (Completed) CZ (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000906-20 Sponsor Protocol Number: LUM001-601 Start Date*: 2015-05-13
    Sponsor Name:Shire Human Genetic Therapies Inc
    Full Title: An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) ...
    Medical condition: Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    17.1 10010331 - Congenital, familial and genetic disorders 10053870 Alagille syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015999-10 Sponsor Protocol Number: XM22-03 Start Date*: 2010-03-02
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study
    Medical condition: Breast cancer high risk stage II, III or IV according to AJCC classification
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006200 Breast cancer stage II PT
    12.0 10006201 Breast cancer stage III PT
    12.0 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 23:21:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA